[go: up one dir, main page]

PT3773715T - Miricizumab no tratamento da colite ulcerosa - Google Patents

Miricizumab no tratamento da colite ulcerosa

Info

Publication number
PT3773715T
PT3773715T PT197222565T PT19722256T PT3773715T PT 3773715 T PT3773715 T PT 3773715T PT 197222565 T PT197222565 T PT 197222565T PT 19722256 T PT19722256 T PT 19722256T PT 3773715 T PT3773715 T PT 3773715T
Authority
PT
Portugal
Prior art keywords
methods
ulcerative colitis
treating ulcerative
treating
colitis
Prior art date
Application number
PT197222565T
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT3773715T publication Critical patent/PT3773715T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT197222565T 2018-03-30 2019-03-28 Miricizumab no tratamento da colite ulcerosa PT3773715T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30

Publications (1)

Publication Number Publication Date
PT3773715T true PT3773715T (pt) 2024-05-27

Family

ID=66429483

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197222565T PT3773715T (pt) 2018-03-30 2019-03-28 Miricizumab no tratamento da colite ulcerosa

Country Status (27)

Country Link
US (2) US12152072B2 (pt)
EP (2) EP4327866A3 (pt)
JP (4) JP7119114B2 (pt)
KR (1) KR102552693B1 (pt)
CN (1) CN111936165A (pt)
AU (2) AU2019243283C1 (pt)
BR (1) BR112020018099A2 (pt)
CA (1) CA3095297A1 (pt)
DK (1) DK3773715T3 (pt)
EA (1) EA202091989A1 (pt)
ES (1) ES2983809T3 (pt)
FI (1) FI3773715T3 (pt)
HR (1) HRP20240904T1 (pt)
HU (1) HUE067445T2 (pt)
IL (2) IL277514B2 (pt)
LT (1) LT3773715T (pt)
MA (1) MA52216B1 (pt)
MD (1) MD3773715T2 (pt)
MX (1) MX2020010269A (pt)
PL (1) PL3773715T3 (pt)
PT (1) PT3773715T (pt)
RS (1) RS65661B1 (pt)
SG (1) SG11202009526RA (pt)
SI (1) SI3773715T1 (pt)
TW (2) TWI837532B (pt)
UA (1) UA128578C2 (pt)
WO (1) WO2019191464A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
BR112022015996A2 (pt) * 2020-02-14 2022-10-11 Janssen Biotech Inc Método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23
US12258393B2 (en) 2020-05-21 2025-03-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
MX2023007933A (es) * 2021-01-06 2023-09-15 Abbvie Inc Métodos para tratar la enfermedad de crohn y la colitis ulcerosa.
US20220372129A1 (en) * 2021-05-20 2022-11-24 Janssen Biotech, Inc. Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
US20240254217A1 (en) * 2021-05-28 2024-08-01 Eli Lilly And Company Anti -il-23p19 antibody regulation of genes involved in ulcerative colitis
WO2024110898A1 (en) * 2022-11-22 2024-05-30 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024191771A1 (en) 2023-03-10 2024-09-19 Eli Lilly And Company Methods of treating ulcerative colitis
WO2024255867A1 (zh) * 2023-06-16 2024-12-19 信达生物制药(苏州)有限公司 重组抗白介素23p19亚基抗体在治疗炎症性肠病中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101252951B (zh) * 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) * 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2019171252A1 (en) * 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Also Published As

Publication number Publication date
TWI744617B (zh) 2021-11-01
IL277514B2 (en) 2024-11-01
TWI837532B (zh) 2024-04-01
MA52216A (fr) 2021-02-17
AU2019243283A1 (en) 2020-09-24
EP3773715A1 (en) 2021-02-17
SG11202009526RA (en) 2020-10-29
JP7331219B2 (ja) 2023-08-22
BR112020018099A2 (pt) 2020-12-22
KR102552693B1 (ko) 2023-07-07
PL3773715T3 (pl) 2024-08-19
UA128578C2 (uk) 2024-08-21
ES2983809T3 (es) 2024-10-24
EA202091989A1 (ru) 2021-01-13
FI3773715T3 (fi) 2024-05-30
TW201946657A (zh) 2019-12-16
NZ767902A (en) 2024-05-31
EP4327866A3 (en) 2024-03-20
IL277514B1 (en) 2024-07-01
IL312807A (en) 2024-07-01
HUE067445T2 (hu) 2024-10-28
US20250034243A1 (en) 2025-01-30
JP2021517156A (ja) 2021-07-15
AU2019243283C1 (en) 2024-05-02
US20210032325A1 (en) 2021-02-04
CN111936165A (zh) 2020-11-13
MX2020010269A (es) 2020-11-06
MD3773715T2 (ro) 2024-10-31
JP7119114B2 (ja) 2022-08-16
LT3773715T (lt) 2024-06-25
TW202206104A (zh) 2022-02-16
SI3773715T1 (sl) 2024-06-28
AU2023248103A1 (en) 2023-11-09
DK3773715T3 (da) 2024-05-27
WO2019191464A1 (en) 2019-10-03
JP2025020134A (ja) 2025-02-12
EP3773715B1 (en) 2024-05-08
US12152072B2 (en) 2024-11-26
AU2019243283B2 (en) 2023-07-27
EP4327866A2 (en) 2024-02-28
MA52216B1 (fr) 2024-07-31
IL312807B1 (en) 2025-02-01
JP7571225B2 (ja) 2024-10-22
RS65661B1 (sr) 2024-07-31
KR20200128101A (ko) 2020-11-11
JP2023166388A (ja) 2023-11-21
IL277514A (en) 2020-11-30
HRP20240904T1 (hr) 2024-10-11
JP2022169562A (ja) 2022-11-09
CA3095297A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
IL277514A (en) Methods for treating ulcerative colitis
ZA202006746B (en) Methods of treatment
HK1259347A1 (zh) 治療結腸炎的方法
ZA201903873B (en) Methods of treating cochlear synaptopathy
IL290069A (en) Methods for treating eye conditions
HK1252692A1 (zh) 治療或者預防蛋白質構象病的方法
IL267199A (en) A method for treating epilepsy
IL272092A (en) Methods for treating changes in behavior
GB201815588D0 (en) Method of treatment
EP3684342C0 (en) TREATMENT METHOD
GB201706406D0 (en) Method of treatment
IL287130A (en) Methods for treating itching
IL279917A (en) Treating ulcerative colitis with brazikumab
PL3356577T3 (pl) Obróbka w kąpieli wytrawiającej
IL272379A (en) Methods for treating cancer using SETDS inhibition
GB201602802D0 (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
ZA201903931B (en) Method of treating meat
SG11201710199PA (en) Methods of treating multiple sclerosis
PT3661510T (pt) Métodos de tratamento de alterações do comportamento
GB201820157D0 (en) Method of treatment
GB201720439D0 (en) Method of treatment
ZA201805402B (en) Treatment of contaminated water
GB201718589D0 (en) Method of treatment
GB201801249D0 (en) Methods of treatment